Spots Global Cancer Trial Database for cml, ph+ all
Every month we try and update this database with for cml, ph+ all cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients | NCT02253277 | Chronic Myeloid... | Nilotinib Ruxolitinib | 18 Years - | Novartis |